<DOC>
	<DOCNO>NCT00453349</DOCNO>
	<brief_summary>To assess efficacy safety oral moxifloxacin compare oral levofloxacin plus oral metronidazole uncomplicated pelvic inflammatory disease ( PID )</brief_summary>
	<brief_title>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Diagnosis uncomplicated PID base absence pelvic tuboovarian abscess pelvic ultrasound and/or laparoscopic examination . Subjects impair liver renal function ; know hypersensitivity study drug , relate compound excipients .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Uncomplicated pelvic inflammatory disease</keyword>
</DOC>